CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 150 enrolled
Drug / intervention
Collagenase Clostridium Histolyticum +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01987986
NCT01987986Phase 2Completed
CompareCT.gov

A Phase 2, Double-blind and Placebo Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy

Endo Pharmaceuticals·interventional·Posted Nov 20, 2013·Updated Oct 5, 2017

In Brief

A Phase 2 clinical trial evaluating Collagenase Clostridium Histolyticum and Placebo for Edematous Fibrosclerotic Panniculopathy (EFP). Completed, enrolled 150 participants across 10 sites.

Detailed Summary

To assess the safety and effectiveness of repeat doses of AA4500 in the treatment of edematous fibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEdematous Fibrosclerotic Panniculopathy (EFP)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 20, 2013
Enrollment StartOct 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.6 years ago

Interventions

Collagenase Clostridium Histolyticumbiological

injectible intervention

Placebobiological